Clinical trial
An Open-label Study, to Assess the Long-term Safety and Clinical Benefit of Droxidopa in Subjects With PAF, Dopamine Beta Hydroxylase Deficiency or Non-diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension
NCT00738062 is registered in ClinicalTrials.gov with Chelsea Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label Study, to Assess the Long-term Safety and Clinical Benefit of Droxidopa in Subjects With PAF, Dopamine Beta Hydroxylase Deficiency or Non-diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension
- Lead sponsor
- Chelsea Therapeutics
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- January 31, 2008
- Completion date
- December 31, 2010
- Enrollment
- 103 (actual)
- Sites
- 54
Conditions
As the registry lists them; a condition with its own page is linked.
dopamine beta hydroxylase deficiency, multiple system atrophy, neurogenic orthostatic hypotension, non-diabetic autonomic neuropathy